Lung Cancer Trial, Recruiting (NCT05167487)

Lung Cancer Trial, Recruiting NCT05167487 Sponsor: Fundación GECP Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05167487 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

You have a type of lung cancer classified as "resectable stage IIIA," meaning surgery was considered possible, and your information is already recorded in a specific lung cancer database or a related clinical trial run by a group called Fundación GECP.
Your cancer was confirmed through a tissue sample (biopsy) to have spread to nearby lymph nodes (called N2 involvement).
You were diagnosed with stage IIIA lung cancer between 2010 and 2017.
You received chemotherapy containing a platinum-based drug before surgery, and then had surgery to remove the cancer.
You were at least 18 years old when you entered the study.
You had a PET/CT scan (a type of full-body imaging scan) at the time of your diagnosis.

Who may not be able to join:

You received a combination of chemotherapy and radiation therapy (chemoradiotherapy) as treatment before surgery.
You did not have surgery to remove the cancer after completing your pre-surgery treatment.
You were diagnosed with lung cancer after June 2017.

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 30 June 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05167487

Sponsor: Fundación GECP

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

More information: https://clinicaltrials.gov/study/NCT05167487

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

"Who might be able to join this trial:

You have a type of lung cancer classified as "resectable stage IIIA," meaning surgery was considered possible, and your information is already recorded in a specific lung cancer database or a related clinical trial run by a group called Fundación GECP.
Your cancer was confirmed through a tissue sample (biopsy) to have spread to nearby lymph nodes (called N2 involvement).
You were diagnosed with stage IIIA lung cancer between 2010 and 2017.
You received chemotherapy containing a platinum-based drug before surgery, and then had surgery to remove the cancer.
You were at least 18 years old when you entered the study.
You had a PET/CT scan (a type of full-body imaging scan) at the time of your diagnosis.

Who may not be able to join:

You received a combination of chemotherapy and radiation therapy (chemoradiotherapy) as treatment before surgery.
You did not have surgery to remove the cancer after completing your pre-surgery treatment.
You were diagnosed with lung cancer after June 2017.

Important: Always verify eligibility with the trial site directly before applying."

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 30 June 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Fundación GECP

Registry

ClinicalTrials.gov

Start date

13 December 2021

Est. completion

1 April 2028

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

To assess pathological response after neoadjuvant treatment as a subrogate endpoint for overall survival and disease-free survival in resectable stage IIIA non-small cell lung cancer patients.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov